Innocoll Inc. - Specializing in the Local Treatment of Pain and Infection


Date	Title
4/30/2008	Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx® GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections

4/17/2008	Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx® GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers

3/13/2008	Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx® BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain

2/19/2008	Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx® GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections

1/4/2008	Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx® BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain

1/2/2008	Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx® GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients

12/18/2007	Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx® GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers

12/17/2007	Innocoll Announces Closing of $30 Million Equity Financing Investment

11/28/2007	Innocoll Receives “Intends to Grant” Notices from the European Patent Office for Two European Patent Applications Related to Novel Wound Healing, Biosurgery and Drug Delivery Applications of its CollaRx® Technology

10/17/2007	Innocoll Files Investigational New Drug Application for its CollaRx® BUPIVACAINE TOPICAL for the Treatment of Painful Chronic Skin Ulcers and Burns

9/26/2007	Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations

9/12/2007	Innocoll Enters Into Collaboration With TGR Biosciences For Development Of a Novel Wound Healing Product

9/10/2007	Innocoll, Inc. and Bourne Partners Announce Joint Venture to Build Leading U.S. Advanced Wound Care Business - Formation of CollMED Laboratories, Inc.

9/6/2007	Innocoll Agrees the Sale of its CollaRx® GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma

8/8/2007	Health Canada Approves Innocoll’s CollaRx® GENTAMICIN SURGICAL IMPLANT

6/6/2007	Innocoll Announces Filing of Investigational New Drug Application for its CollaRx® GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections

4/24/2007	Innocoll Announces Outcome of FDA Meeting to Commence Phase 3 Development of its CollaRx® GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections

4/11/2007	Innocoll Files CollaRx® GENTAMICIN SURGICAL IMPLANT in Australia

4/4/2007	Innocoll Receives FDA Approval to Commence Phase 2 Clinical Development with its CollaRx® BUPIVACAINE IMPLANT for the Management of Post-operative Pain

3/29/2007	Innocoll Files US and Irish Patent Applications for its CollaRx® BUPIVACAINE IMPLANT for the Management of Post-operative Pain

3/22/2007	Innocoll Files CollaRx® GENTAMICIN SURGICAL IMPLANT in Canada and Receives Canadian Medical Devices Conformity Assessment System (CMDCAS) Certification

3/1/2007	Innocoll Announces Filing of Investigational New Drug Application for its CollaRx®BUPIVACAINE IMPLANT for the Management of Post-operative Pain

2/5/2007	Innocoll Receives BfArM Approval for a New Version of its CollaRx® Gentamicin Surgical Implant in Germany

1/22/2007	Innocoll Receives FDA Approval to Commence a Phase 2 Clinical Trial for the Topical Treatment of Infected Diabetic Foot Ulcers With its CollaRx® GENTAMICIN

1/17/2007	Innocoll Announces Expansion of the Distribution Partnership for its CollaRx® GENTAMICIN SURGICAL IMPLANT with BurnsAdler to Include Brazil and Dominican Republic and a Separate Promotional Agreement Between BurnsAdler and Serral for the Same Product in Mexico

11/9/2006	Innocoll Announces Investigational New Drug Application Filing for its CollaRx® GENTAMICIN as a Topical Treatment for Infected Diabetic Foot Ulcers

10/12/2006	Innocoll, Inc. Receives FDA Approval for CollaGUARD™, a Collagen-Based Advanced Wound Care Product

8/01/2006	Innocoll Announces a Distribution Partnership for Central and South America and the Caribbean for its CollaRx ™ Gentamicin Surgical Implant

4/26/2006	Innocoll Announces Launch of a New Version of its CollaRx ™ Gentamicin Surgical Implant Specially Designed for Use in Cardiac Surgery

4/04/2006	Innocoll Announces Additional Distribution Arrangements in the Middle East and the Commonwealth of Independent States for CollaRx Gentamicin Surgical Implant

3/30/2006	Innocoll Announces a Distribution Agreement in the Russian Federation for CollaRx ™ Gentamicin Surgical Implant

3/28/2006	Innocoll Announces Initiation of Phase IIA Clinical Study of Bupivacaine Collagen Sponge

3/7/2006	Innocoll Announces Approval to Promote its CollaRx ™ Gentamicin Surgical Implant in Norway

2/2/2006	Innocoll Announces Additional Distribution Agreements for CollaRx™ in the Middle East

1/27/2006	Innocoll Announces First Asian Distribution Agreement for CollaRx™ GENTAMICIN SURGICAL IMPLANT in Hong Kong

12/20/2005	Innocoll, Inc. Files US 510K for CollaGUARD™, a Collagen-based Advanced Would Care Product

12/12/2005	Innocoll, Inc. Announces New Distribution Agreements for CollaRx ™ Gentamicin Surgical Implant

9/08/2005	Innocoll, Inc. Enters Into Agreement with Medexis for Development of a Wound Healing Product

7/28/2005	Innocoll, Inc. Enters Into Agreement with Surgical-IOC for Development of Adhesion Barrier Product

7/14/2005	Innocoll, Inc. Announces Acquisition of Marketing Rights to CollaRx ™ Gentamicin Surgical Implant

6/17/2005	Innocoll, Inc. Announces Collaboration with the University of Iowa for Evaluation of LiquiColl® as Gene Delivery Vehicle

3/9/2005	Innocoll, Inc. Granted Two Patents for Wound Healing Products

12/1/2004	Innocoll Establishes Operations in Ireland and Creates New Division

Site Map

Disclaimer